MacroGenics argues that margetuximab works by tweaking the “Fc” part of Herceptin – the tail of the ‘Y’ shaped antibody – so that it interacts more efficiently with the immune system ...

MacroGenics has altered the “Fc” part of the antibody – the tail of the ‘Y’-shaped molecule – so that it interacts more efficiently with the immune system when engaged with a cancer cell.

MacroGenics has a strong cash position ... three molecules with our three core platforms, our FC engineered, our DART bispecific and our ADC platform are being pursued for treatments for various ...

MacroGenics has secured $475 million ... prostate cancer using our three proprietary technologies, FC engineering, our bispecific DART technology, as well as our ADC molecules.